Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.

An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hair follicles from DHT.

Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A user increased their dutasteride dosage from 0.5mg to 1mg daily, resulting in a rise in DHT levels from 148 pg/mL to 281 pg/mL, and is considering switching back to finasteride due to continued hair loss. Replies suggest retesting and emphasize the importance of bloodwork before starting treatments.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

An 18-year-old is concerned about their visible hairline and low hair density when considering a buzz cut. They are worried about potential negative reactions.

A user is seeking recommendations for purchasing Minichek 5% solution, a PG-free minoxidil, due to a contact allergy to propylene glycol. They are looking for an affordable option comparable in price to Kirkland or Amazon brand minoxidil.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.

Fluridil is considered safe with moderate effectiveness for hair loss, but its cost of €50 per month is seen as high compared to other treatments. The user is considering Pyri as a more cost-effective option and is seeking success stories about Fluridil's ability to stop hair loss without side effects.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.

The conversation discusses a prescribed hair loss treatment combining 12.5% minoxidil with tretinoin, azelaic acid, and topical finasteride, costing $55 a month. One user criticizes the packaging for degrading tretinoin, another suggests it's an overpriced option and recommends topical dutasteride as an alternative due to its higher molecular weight and lower systemic absorption.

The user started using topical finasteride 0.025% and minoxidil 5% twice daily, seeing initial improvement but later experiencing shedding and scalp pain. They are considering increasing the finasteride dose to 0.05% while using keto shampoo and dermarolling, and are debating the effectiveness of low versus standard doses of finasteride.

The user experienced significant hair regrowth using 5% Minoxidil, 1mg Finasteride, and Nizoral, with minimal side effects like occasional dandruff. Shedding occurred initially but led to positive results over time.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

A 22-year-old male experiencing diffuse hair thinning has been using finasteride, initially at 0.5mg and then 1mg daily, but sees no improvement. Despite correcting a vitamin D deficiency and noticing some new hair growth, he questions the effectiveness of finasteride.

The conversation is about finding the best method to lower scalp prolactine, with suggestions like P5P and Melatonin. The user also mentions HMI115 as a potential treatment and seeks feedback from those who have tried these methods.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

A 28-year-old is assessing their hair loss on the Norwood scale, considering adding topical minoxidil and dermastamping to their current regimen of oral finasteride and minoxidil. They feel their hair loss is worsening and seek opinions on their condition.

Low doses of finasteride, even as low as 0.25 mg, can effectively prevent hair loss without significantly lowering DHT levels. Combining finasteride with natural DHT-lowering solutions may achieve similar results to higher doses.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.